BACKGROUND: Data are limited about the effectiveness of pediatric antiretroviral therapy (ART) in low-income countries. METHODS: We report the outcomes of consecutively treating 236 human immunodeficiency virus type 1 (HIV-1)-infected treatment-naive children with triple ART in Port-au-Prince, Haiti, between 1 May 2003 and 30 April 2006. RESULTS: Kaplan-Meier survival analysis at follow-up demonstrated that 191 children (81%) remained in care, 21 (9%) were dead, and 24 (10%) were lost to follow-up. Independent baseline predictors of mortality were age <18 months, CD4(+) T cell percentage < or =5%, and weight-for-age Z score (WAZ) less than -3. Twelve months into ART, 56% of tested subjects had undetectable HIV-1 RNA loads. Median CD4(+) T cell percentages at 12 months increased by 15%, 11%, and 5% in children with baseline percentages of < or =5%, 6%-24%, and > or =25%, respectively (P<.01). The median WAZ at 12 months increased by 1.0, 0.6, and 0.2 in children with baseline WAZ less than -2, -2 to -1.1, and -1 or more, respectively (P<.01). CONCLUSION: With continuous donor support, trained providers, and the availability of pediatric antiretroviral drug formulations, it proved feasible to deliver pediatric ART in Haiti. The effectiveness of this program should encourage efforts to make ART available for HIV-infected children in poor countries.
BACKGROUND: Data are limited about the effectiveness of pediatric antiretroviral therapy (ART) in low-income countries. METHODS: We report the outcomes of consecutively treating 236 human immunodeficiency virus type 1 (HIV-1)-infected treatment-naive children with triple ART in Port-au-Prince, Haiti, between 1 May 2003 and 30 April 2006. RESULTS: Kaplan-Meier survival analysis at follow-up demonstrated that 191 children (81%) remained in care, 21 (9%) were dead, and 24 (10%) were lost to follow-up. Independent baseline predictors of mortality were age <18 months, CD4(+) T cell percentage < or =5%, and weight-for-age Z score (WAZ) less than -3. Twelve months into ART, 56% of tested subjects had undetectable HIV-1 RNA loads. Median CD4(+) T cell percentages at 12 months increased by 15%, 11%, and 5% in children with baseline percentages of < or =5%, 6%-24%, and > or =25%, respectively (P<.01). The median WAZ at 12 months increased by 1.0, 0.6, and 0.2 in children with baseline WAZ less than -2, -2 to -1.1, and -1 or more, respectively (P<.01). CONCLUSION: With continuous donor support, trained providers, and the availability of pediatric antiretroviral drug formulations, it proved feasible to deliver pediatric ART in Haiti. The effectiveness of this program should encourage efforts to make ART available for HIV-infectedchildren in poor countries.
Authors: William B Lober; Christina Quiles; Steve Wagner; Rachelle Cassagnol; Roges Lamothes; Don Rock Pierre Alexis; Patrice Joseph; Perri Sutton; Nancy Puttkammer; Mari M Kitahata Journal: AMIA Annu Symp Proc Date: 2008-11-06
Authors: Consuelo M Beck-Sagué; Jessy Dévieux; Maria Claudia Pinzón-Iregui; Leonel Lerebours-Nadal; Rosa Abreu-Pérez; Rachel Bertrand; Vanessa Rouzier; Stephanie Gaston; Gladys Ibanez; Mina Halpern; Jean W Pape; Patricia Dorceus; Sharice M Preston; Andrew G Dean; Stephen W Nicholas; Ileana Blasini Journal: AIDS Date: 2015-06 Impact factor: 4.177
Authors: Paula Braitstein; Adrian Katshcke; Changyu Shen; Edwin Sang; Winstone Nyandiko; Vincent Ooko Ochieng; Rachel Vreeman; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Samwel Ayaya Journal: Trop Med Int Health Date: 2010-05-14 Impact factor: 2.622
Authors: Jean W Pape; Patrice D Severe; Daniel W Fitzgerald; Marie M Deschamps; Patrice Joseph; Cynthia Riviere; Vanessa Rouzier; Warren D Johnson Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: Macarthur Charles; Francine Noel; Paul Leger; Patrice Severe; Cynthia Riviere; Carole Anne Beauharnais; Erica Miller; John Rutledge; Heejung Bang; Wesley Shealey; Richard T D'Aquila; Roy M Gulick; Warren D Johnson; Peter F Wright; Jean William Pape; Daniel W Fitzgerald Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408